Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

The order is a blow to the pharmaceutical industry, which is already bracing for Trump's planned tariffs on prescription ...

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of prescription drugs in the U.S. by as much as 80%.

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Shares of major U.S. drugmakers Eli Lilly, Pfizer, Merck, AbbVie and Amgen fell between 2% and 4% in premarket trading Monday ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

China trade talks that resulted in a sharp reduction in tariffs. Treasury yields are rising and Bitcoin is holding well above $100,000.

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...